Central and East European Oncology Group

PathIES - Intergroup Exemestane Study Pathology Sub-Study

Study team

Chief Investigator: Ewa Szutowicz-Zielińska, MD, PhD



Study Coordinator

Anna  Gładysz, MSc.GUMed

Study title

Intergroup Exemestane Study Pathology Sub-Study

Start date

01 September 2007

Study status



The Intergroup Exemestane Study (IES) has shown improved disease free survival in postmenopausal women with early breast cancer who switched to the aromatase inhibitor (AI) exemestane, after 2-3 years of tamoxifen therapycompared to those who received tamoxifen alone for a total of five years of adjuvant therapy (Coombes et al., 2007). Despite the overall benefit demonstrated it is not yet possible to identify upfront which women would benefit from switching to exemestane.

PathIES is an academically led translational study that aims to address this question. It involves the retrospective collection of archived formalin fixed paraffin embedded (FFPE) blocks containing tissue from the primary tumour, recurrent tumour and contralateral breast carcinomas from women participating in the IES. Tumour tissue will be analysed for a set of biomarkers that have been shown to impact on sensitivity to AIs and/or tamoxifen.

By correlating the results of this analysis with patient outcome, we hope to identity those biomarkers that may be determinants of response to these treatment


Medical University of Gdańsk
Department of Oncology and Radiotherapy
7 Dębinki Street, 80-211 Gdańsk, Poland
phone: +48 58 584 4560
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.